Abstract Library

#4665 Prognostic value of systemic inflammatory parameters in neuroendocrine tumour patients treated with peptide receptor radionuclide therapy – Preliminary results

Introduction: PRRT (177Lu-Dotatate) is a therapeutic option for advanced NETs (neuroendocrine tumours). Systemic inflammatory parameters, such as NLR, PLR, SII, and other ratios derived from complete blood counts, are considered prognostic markers in NETs and other malignancies.

Conference:

Presenting Author: Maciejewski A

Authors: Maciejewski A, Komarnicki P, Musiałkiewicz J, Gut P, Ruchała M,

Keywords: neuroendocrine tumour, PRRT, systemic inflammatory parameter, PLR, prognostic biomarker,

#4657 Should we use the growth modulation index (GMI) in response assessment in G2 neuroendocrine tumours (NETs)?

Introduction: Grade 2 (G2) neuroendocrine tumours (NETs) exhibit diverse behaviours ranging from indolent to aggressive malignancies. Growth Modulation Index (GMI) is the ratio between time to progression (TTP) with a line of therapy (TTPn) and that of the previous line of therapy (TTPn-1). A GMI value equal to or greater than 1,33 has been suggested as an indicator of clinical effectiveness beyond traditional metrics.

Conference:

Presenting Author: Bertuzzi A

Authors: Bertuzzi A, Ferrillo G, Laffi A, Evangelista L, Jandric J,

Keywords: growth modulation index (GMI), G2 gastroenteropancreatic neuroendocrine tumour (GEP-NET), tumour response assessment,

#4609 External validation of Rachel score: A prognostic tool for lung neuroendocrine tumours

Introduction: Lung NETs are a heterogeneous group of tumours with variegated clinical presentation and course. The histological subtype (TC vs AC) and TNM stage are established prognostic factors. In a previous work by our group, we developed a prognostic model named Rachel score, with a satisfactory ability to predict OS and PFS in this population.

Conference:

Presenting Author: La Salvia A

Authors: La Salvia A, Marcozzi B, Lamberti G, Manai C, Mazzilli R,

Keywords: lung neuroendocrine tumour, prognostic tool, Rachel score, external cohort, validation,

#4566 Predictive value of high-risk histopathological- and molecular criteria for lymph node metastasis in appendiceal neuroendocrine tumours

Introduction: Appendiceal neuroendocrine tumours (aNET) are rare neoplasms for which consensus is needed for follow-up and additional treatment. To unravel the factors behind aNET which showed lymph node metastasis (LNM) in additional right hemicolectomy (RH), we evaluated high-risk histopathological parameters in aNETs and studied molecular parameters.

Conference:

Presenting Author: Bremer B

Authors: Bremer B, Kyriskozoglou V, El Moumni M, Heideman D, Walenkamp-Hageman A,

Keywords: Appendix NET, High-risk histopathological criteria, Serotonin, Driver mutation, Right Hemicolectomy,

#4561 Prognostic value of pre-therapeutic and interim SSTR PET in patients with GI-NET receiving peptide receptor radionuclide therapy

Introduction: Baseline and interim (after 2 cycles) somatostatin receptor (SSTR)-directed PET/CTs are essential in patients with gastrointestinal neuroendocrine tumours (GI-NET) undergoing peptide radioreceptor therapy (PRRT).

Conference:

Presenting Author: Weber S

Authors: Weber S, Alwers S, Beissert M, Buck A, Werner R,

Keywords: somatostatin, PRRT, PFS, SUVmean,